The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 244-250

  Li, Liwen ^a   Ji, Hui ^a   Sheng, Liang ^a   Zhang, Yihua ^a   Lai, Yisheng ^a   Chen, Xiaorong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti inflammatory effect; Arachidonic acid; Cyclooxygenase lipoxygenase inhibitor; Gastrointestinal injury; Inflammation

Indexed keywords

1 METHYL 1,5 DIHYRO 2 AMINO 5 [4 (MESYL)BENZYLIDINE] 4H IMIDAZOLE 4 ONE MESILATE; ACETIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CALCIMYCIN; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DARBUFELONE; DICLOFENAC; ICOSANOID; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; THROMBOXANE B2; UNCLASSIFIED DRUG; ZLJ 6;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; ENZYME INHIBITION; FATTY ACID METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LEUKOCYTE; MALE; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PAW EDEMA; PERITONEUM; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; RAT; STOMACH HEMORRHAGE; STOMACH ULCER; WRITHING TEST;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; EDEMA; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; LEUKOCYTES; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; THROMBOXANE B2;

EID: 62149090256     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.032     Document Type: Article

References (27)

1. Algate D.R., Agustin J., Atterson P.R., Beard D.J., Jobling C.M., Laufer S., Munt P.L., and Tries S. General pharmacology of (2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyr-rolizine)-acetic acid in experimental animals. Arzneim Forsch/Drug Res. 45 (1995) 272-276
2. Allison M.C., Howatson A.G., Torrance C.J., Lee F.D., and Russell R.I. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N. Engl. J. Med. 327 (1992) 749-754
3. Argentieri D.C., Ritchie D.M., Ferro M.P., Kirchner T., Wachter M.P., Anderson D.W., Rosenthale M.E., and Capetola R.J. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J. Pharmacol. Exp. Ther. 271 (1994) 1399-1408
4. Bertolini A., Ottani A., and Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol. Res. 44 (2001) 437-450
5. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., and Chan C.C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 45 (1996) 68-74
6. Eskra J.D., Pereira M.J., and Ernest M.J. Solid-phase extraction and high-performance liquid chromatography analysis of lipoxygenase pathway products. Anal. Biochem. 154 (1986) 332-337
7. Georges, and Halpern M. COX-2 inhibitors: a story of greed, deception and death. Inflammopharmacology 13 (2005) 419-425
8. Graham D.Y., Smith J.L., Holmes G.I., and Davies R.O. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin. Pharmacol. Ther. 38 (1985) 65-70
9. Heller A., Kock T., Schmeck J., and Van Ackern K. Lipid mediators in inflammatory disorders. Drugs 55 (1998) 487-496
10. Horizoe T., Nagakura N., Chiba K., Shirota H., Shinoda M., Kobayashi N., Numata H., Okamoto Y., and Kobayashi S. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm. Res. 47 (1998) 375-383
11. Kapui Z., Boér K., Rósza I., Blaskó G., and Hermecs I. Investigations of indomethacin-induced gastric ulcers in rats. Arzneimittelforschung 43 (1993) 767-771
12. Klesser B., Bias P., and Buchner A. Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after 4 weeks of treatment. Ann. Rheum. Dis. 61 Suppl.1 (2002) 130
13. Kobayashi K., Fukuda T., Higuchi K., Nakamura H., and Arakawa T. Role of leukotrienes in indomethacin-induced mucosal damage in rats. J. Clin. Gastroenterol. 17 Suppl 1 (1993) S11-S14
14. Moroney M.A., Forder R.A., Carey F., and Hoult J.R. Differential regulation of 5-lipoxygenase and cyclooxygenase pathways of arachidonate metabolism in rat peritoneal leukocytes. Br. J. Pharmacol. 101 (1990) 128-132
15. Oketani K., Nagakura N., Harada K., and Inoue T. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A synthetase, on eicosanoid production. Eur. J. Pharmacol. 422 (2001) 209-216
16. Pairet M., and van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm. Res. 47 Suppl. 2 (1998) S93-S101
17. 4 inhibitors on experimentally induced lesions in the rats. Res. Commun. Chem. Pathol. Pharmacol. 58 (1987) 15-25
18. 4 in rat gastric mucosa. Prostaglandins 31 (1986) 283-293
19. Rainsford K.D. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal anti-inflammatory drugs in mice. Agents Actions. 21 (1987) 316-319
20. Raskin J.B. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am. J. Med. 106 (1999) 3S-12S
21. Sala A., Recio M.C., Schinella G.R., Máñez S., Giner R.M., and Ríos J.L. A new dual inhibitor of arachidonate metabolism isolated from Helichrysum italicum. Eur. J. Pharmacol. 460 (2003) 219-226
22. Salvemini D., Wang Z.Q., Wyatt P.S., Bourdon D.M., Marino M.H., Manning P.T., and Currie M.G. Nitric oxide: a key mediator in the early and late phases of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 118 (1996) 829-838
23. Soll A.H., and McCarthy D. NSAID-related gastrointestinal complications. Clin. Cornerstone 1 (1999) 42-56
24. Song Y., Connor D.T., and Doubleday R. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J. Med. Chem. 42 (1999) 1151-1160
25. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231 (1971) 232-239
26. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M.B., and Cirino G. Novel nonsteriodal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107 (1994) 173-179
27. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U. S. A. 22 (1999) 7563-7568